Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PRAX Praxis Precision Medicines, Inc.

交易中 12-09 12:52:00 EST

265.54

-5.44

-2.01%

最高278.44	最低262.39	成交量27.98万
今开271.00	昨收270.98	日振幅5.92%
总市值66.40亿	流通市值52.55亿	总股本2,501万
成交额7,483万	换手率1.41%	流通股本1,979万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":265.54,"timestamp":1765302719669,"preClose":270.98,"halted":0,"volume":279812,"delay":0,"floatShares":19790700,"shares":25007171,"eps":-12.922727,"marketStatus":"交易中","change":-5.44,"latestTime":"12-09 12:52:00 EST","open":271,"high":278.4399,"low":262.3901,"amount":74827473.34036,"amplitude":0.059229,"askPrice":265.83,"askSize":3,"bidPrice":264.61,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-12.922727,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765314000000},"marketStatusCode":2,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":270.98,"preHourTrading":{"tag":"盘前","latestPrice":271.1,"preClose":270.98,"latestTime":"09:29 EST","volume":2534,"amount":695442.2616399999,"timestamp":1765290597018},"postHourTrading":{"tag":"盘后","latestPrice":273.8032,"preClose":270.98,"latestTime":"19:57 EST","volume":48071,"amount":13027626.2307,"timestamp":1765241854827},"volumeRatio":0.382381,"impliedVol":0.8215,"impliedVolPercentile":0.156},"requestUrl":"/m/hq/s/PRAX","defaultTab":"news","newsList":[{"id":"1180993297","title":"Praxis Precision Medicines, Inc.：单药疗法研究Power3计划于2026年上半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1180993297","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180993297?lang=zh_cn&edition=full","pubTime":"2025-12-09 05:47","pubTimestamp":1765230438,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.：单药疗法研究Power3计划于2026年上半年启动","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"1130139994","title":"Praxis Precision Medicines公布Embold研究关于Relutrigine在Scn2a和Scn8a发育性及癫痫脑病中的积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1130139994","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130139994?lang=zh_cn&edition=full","pubTime":"2025-12-05 05:12","pubTimestamp":1764882729,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公布Embold研究关于Relutrigine在Scn2a和Scn8a发育性及癫痫脑病中的积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","BK4139","LU0889565916.HKD","PRAX"],"gpt_icon":0},{"id":"1199927050","title":"Praxis Precision Medicines与FDA召开积极的NDA前会议，讨论Ulixacaltamide在特发性震颤中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1199927050","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199927050?lang=zh_cn&edition=full","pubTime":"2025-12-05 05:02","pubTimestamp":1764882151,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines与FDA召开积极的NDA前会议，讨论Ulixacaltamide在特发性震颤中的应用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139","PRAX"],"gpt_icon":0},{"id":"1166387197","title":"Praxis Precision Medicines：加速推进Relutrigine在Scn2a和Scn8a Dee患者中的开发计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1166387197","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166387197?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:01","pubTimestamp":1762347693,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines：加速推进Relutrigine在Scn2a和Scn8a Dee患者中的开发计划","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","BK4139"],"gpt_icon":0},{"id":"1116109522","title":"Praxis Precision Medicines 发布公司更新及2025年第三季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1116109522","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116109522?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:01","pubTimestamp":1762347691,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines 发布公司更新及2025年第三季度财务业绩","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX"],"gpt_icon":0},{"id":"1158510697","title":"Praxis宣布在Scn2a和Scn8a Dee患者中推进Relutrigine的加速开发计划，获得FDA积极反馈","url":"https://stock-news.laohu8.com/highlight/detail?id=1158510697","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158510697?lang=zh_cn&edition=full","pubTime":"2025-11-04 21:01","pubTimestamp":1762261279,"startTime":"0","endTime":"0","summary":"Praxis宣布在Scn2a和Scn8a Dee患者中推进Relutrigine的加速开发计划，获得FDA积极反馈","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX"],"gpt_icon":0},{"id":"1106249696","title":"异动解读 | Praxis Precision Medicines股价盘中大涨9.97%，新药临床试验成功推动股价持续攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=1106249696","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106249696?lang=zh_cn&edition=full","pubTime":"2025-10-17 21:32","pubTimestamp":1760707948,"startTime":"0","endTime":"0","summary":"生物制药公司Praxis Precision Medicines周五盘中大涨9.97%，延续了前一交易日的强劲涨势。这一显著涨幅主要源于该公司实验性药物在临床试验中取得突破性进展，以及随后宣布的大规模融资计划。Praxis Precision Medicines本周早些时候宣布，其用于治疗本质性震颤的实验性药物ulixacaltamide在两项关键性三期临床试验中均达到了预定的主要终点。紧随临床试验成功之后，Praxis宣布了一项5.25亿美元的公开募股计划。Praxis Precision Medicines股价的持续上涨反映了投资者对公司未来发展前景的乐观预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7fa23516ca85b1156f2152e8f7e5531d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PRAX"],"gpt_icon":0},{"id":"1152445060","title":"异动解读 | Praxis Precision Medicines盘前大涨5.71%，新药临床试验获重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1152445060","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152445060?lang=zh_cn&edition=full","pubTime":"2025-10-17 16:52","pubTimestamp":1760691155,"startTime":"0","endTime":"0","summary":"生物制药公司Praxis Precision Medicines今日盘前大涨5.71%，延续了前一交易日的强劲涨势。这一显著涨幅主要源于公司宣布其用于治疗运动障碍的实验性药物ulixacaltamide在两项关键性三期临床试验中取得突破性进展。这一突破性进展对Praxis Precision Medicines具有重要意义，因为目前市场上尚无获批的专门针对本质性震颤的治疗方法。此外，Praxis还宣布计划发行新股，以利用其飙升的股价进行融资。这一系列利好消息推动了公司股价的持续上涨，反映了市场对Praxis Precision Medicines未来发展前景的乐观预期。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PRAX"],"gpt_icon":1},{"id":"1167533692","title":"异动解读 | Praxis Precision Medicines夜盘大涨7.97%，新药临床试验取得突破性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1167533692","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167533692?lang=zh_cn&edition=full","pubTime":"2025-10-17 08:40","pubTimestamp":1760661628,"startTime":"0","endTime":"0","summary":"10月16日晚间，生物制药公司Praxis Precision Medicines股价大涨7.97%，延续了日间交易中的强劲涨势。这一显著涨幅主要源于该公司宣布其用于治疗运动障碍的实验性药物ulixacaltamide在两项关键性三期临床试验中取得突破性进展。这一突破性进展对Praxis Precision Medicines具有重要意义，因为目前市场上尚无获批的专门针对本质性震颤的治疗方法。这一系列利好消息推动了公司股价在日间和夜间交易中的持续上涨，反映了市场对Praxis Precision Medicines未来发展前景的乐观预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PRAX"],"gpt_icon":1},{"id":"2576772599","title":"Uniqure N.V.盘中异动 临近收盘股价大跌5.01%报59.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576772599","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576772599?lang=zh_cn&edition=full","pubTime":"2025-10-17 03:33","pubTimestamp":1760643232,"startTime":"0","endTime":"0","summary":"北京时间2025年10月17日03时33分，Uniqure N.V.股票出现异动，股价大幅下跌5.01%。截至发稿，该股报59.69美元/股，成交量187.013万股，换手率3.04%，振幅8.48%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.36%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101703335297325a88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101703335297325a88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","LU0109394709.USD","BK4139","PRAX","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2575740532","title":"美股异动 | 特发性震颤药物研究出现积极进展 Praxis Precision Medicines(PRAX.US)飙升240%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575740532","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575740532?lang=zh_cn&edition=full","pubTime":"2025-10-16 22:31","pubTimestamp":1760625068,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，Praxis Precision Medicines早盘飙升240%，创三年新高，报194.90美元。消息面上，该公司宣布特发性震颤药物Ulixacaltamide在两项关键III期研究中达到主要终点：Study 1显示第8周Modified ADL-11评分改善4.3分p<0.0001，所有关键次要终点均具统计学显著性;Study 2显示维持效果显著p=0.0369，且第一个关键次要终点具统计学显著性p=0.0042。Ulixacaltamide安全性数据良好，两项研究中未出现药物相关严重不良事件，耐受性与既往试验一致。公司向FDA提交了Ulixacaltamide的新药预申请pre-NDA会议请求，推进药物审批进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 特发性震颤药物研究出现积极进展 Praxis Precision Medicines(PRAX.US)飙升240%","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","PRAX"],"gpt_icon":0},{"id":"2576565703","title":"万春医药盘中异动 股价大涨6.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576565703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576565703?lang=zh_cn&edition=full","pubTime":"2025-10-16 21:39","pubTimestamp":1760621942,"startTime":"0","endTime":"0","summary":"北京时间2025年10月16日21时39分，万春医药股票出现异动，股价快速上涨6.06%。截至发稿，该股报1.75美元/股，成交量203股，换手率0.00%，振幅1.75%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。万春医药股票所在的生物技术行业中，整体涨幅为0.65%。万春医药公司简介：BeyondSpring Inc从事临床阶段的生物制药活动，专注于癌症疗法的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016213902a6bd2214&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016213902a6bd2214&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PRAX","BYSI"],"gpt_icon":0},{"id":"1130968739","title":"Praxis Precision Medicines 股价大幅上涨，运动障碍药物在两项试验中达成主要目标，涨幅高达 180%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130968739","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130968739?lang=zh_cn&edition=full","pubTime":"2025-10-16 21:33","pubTimestamp":1760621597,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines 股价几乎上涨三倍，运动障碍药物在两项试验中符合主要目标，最新涨幅达到 180%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX"],"gpt_icon":0},{"id":"1158794470","title":"Praxis Precision Medicines高管表示公司已完成80%的NDA提交相关文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1158794470","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158794470?lang=zh_cn&edition=full","pubTime":"2025-10-16 20:38","pubTimestamp":1760618295,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines高管表示，公司已完成80%的所有与NDA提交相关的文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX"],"gpt_icon":0},{"id":"1156431432","title":"Praxis Precision Medicines股价在盘前交易中上涨85%，因运动障碍药物满足两项临床试验的主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1156431432","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156431432?lang=zh_cn&edition=full","pubTime":"2025-10-16 19:09","pubTimestamp":1760612981,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines股价在盘前交易中上涨85%，因其运动障碍药物满足了两项临床试验的主要目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","BK4139"],"gpt_icon":0},{"id":"1180112461","title":"Praxis Precision Medicines Inc - 研究1中的所有关键次要终点均具有统计学意义","url":"https://stock-news.laohu8.com/highlight/detail?id=1180112461","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180112461?lang=zh_cn&edition=full","pubTime":"2025-10-16 19:05","pubTimestamp":1760612711,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc - 研究1中的所有关键次要终点均具有统计学意义","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX"],"gpt_icon":0},{"id":"1125623010","title":"Praxis Precision Medicines, Inc. - 2号研究达到预定主要终点，Ulixacaltamide显示出卓越的维持效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1125623010","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125623010?lang=zh_cn&edition=full","pubTime":"2025-10-16 19:04","pubTimestamp":1760612684,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. - 2号研究达到预定主要终点，Ulixacaltamide显示出卓越的维持效果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","BK4139"],"gpt_icon":0},{"id":"1157673011","title":"Praxis Precision Medicines, Inc. - 第二项研究的第一个关键次要终点显示Ulixacaltamide治疗患者相较于安慰剂具有更佳疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1157673011","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157673011?lang=zh_cn&edition=full","pubTime":"2025-10-16 19:04","pubTimestamp":1760612660,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. - 第二项研究的第一个关键次要终点显示Ulixacaltamide治疗患者相较于安慰剂具有更佳疗效","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","BK4139"],"gpt_icon":0},{"id":"1164461218","title":"Praxis Precision Medicines公布基本震颤Essential3项目中Ulixacaltamide HCl两项关键性三期研究的积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1164461218","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164461218?lang=zh_cn&edition=full","pubTime":"2025-10-16 19:01","pubTimestamp":1760612475,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公布基本震颤Essential3项目中Ulixacaltamide HCl两项关键性三期研究的积极顶线结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX"],"gpt_icon":0},{"id":"1101553160","title":"异动解读 | Praxis Precision Medicines股价盘中大跌10.18%，二季度业绩不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1101553160","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101553160?lang=zh_cn&edition=full","pubTime":"2025-08-04 21:45","pubTimestamp":1754315149,"startTime":"0","endTime":"0","summary":"周一盘中，生物制药公司Praxis Precision Medicines股价大跌10.18%，引发市场广泛关注。这一显著跌幅主要源于公司刚刚公布的2025年第二季度财务业绩未能达到市场预期。根据最新发布的财报，Praxis Precision Medicines第二季度每股亏损3.31美元，略高于分析师预期的3.3美元亏损。作为一家专注于中枢神经系统疾病治疗的生物制药公司，Praxis Precision Medicines的财务表现反映了该行业面临的挑战。尽管公司最近报告其药物Vormatrigine展现出良好的安全性特征，但投资者似乎更关注当前的财务状况。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PRAX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":0.4682},{"period":"1month","weight":0.6109},{"period":"3month","weight":5.7694},{"period":"6month","weight":5.0765},{"period":"1year","weight":2.8795},{"period":"ytd","weight":2.521}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0189},{"period":"3month","weight":0.0512},{"period":"6month","weight":0.1368},{"period":"1year","weight":0.1247},{"period":"ytd","weight":0.1664}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Praxis Precision Medicines, Inc.于2015年9月22日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，将遗传见解转化为中枢神经系统（CNS）治疗方法的发展，CNS是以神经元失衡为特征的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.344924},{"month":2,"riseRate":0.2,"avgChangeRate":-0.21435},{"month":3,"riseRate":0.2,"avgChangeRate":-0.183614},{"month":4,"riseRate":0.2,"avgChangeRate":-0.018417},{"month":5,"riseRate":0.4,"avgChangeRate":-0.124101},{"month":6,"riseRate":0.4,"avgChangeRate":-0.094382},{"month":7,"riseRate":0.6,"avgChangeRate":0.167978},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.186468}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Praxis Precision Medicines, Inc.(PRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Praxis Precision Medicines, Inc.(PRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}